Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) announced new research for treating Primary Sclerosing Cholangitis (PSC), a rare liver disease, at their R&D Day 2025. The company unveiled lead candidates, including ESP-1336, which are novel allosteric inhibitors of ATP citrate lyase (ACLY) targeting hepatic inflammation and fibrosis.
The preclinical data shows promising results in reducing liver injury, inflammation, and fibrosis across multiple PSC-relevant models. The company's research utilized multi-omics and phenome-wide association studies to identify ACLY mechanisms linked to bile duct injury and PSC progression.
The market opportunity is estimated at over $1 billion annually, with approximately 76,000 diagnosed PSC patients across the U.S. and Europe as of 2024. The program may be eligible for Orphan Drug and Fast Track designations from the FDA.
Esperion (NASDAQ: ESPR) has announced it will release its first quarter 2025 financial results on Tuesday, May 6, 2025, before market opening. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients.
The company is also advancing its next generation program focusing on ATP citrate lyase inhibitors (ACLYi), utilizing new insights into structure and function for rational drug design of highly potent and specific inhibitors with allosteric mechanisms.
Esperion (NASDAQ: ESPR) has announced an upcoming R&D Day scheduled for April 24, 2025, at 9:00 a.m. ET in New York City. The event will showcase the company's research developments in ATP citrate lyase (ACLY) biology and its therapeutic applications for various life-threatening conditions.
The presentation will focus on how ACLY inhibitors could treat rare and chronic liver and kidney diseases. Esperion plans to reveal a new indication and introduce their lead candidate's development pathway. The event will feature key opinion leaders including Dr. Christos S. Mantzoros from Harvard Medical School and Dr. David E. Cohen from Brigham and Women's Hospital.
A live webcast will be available with pre-registration required on Esperion's website Investor section, with replay available for approximately 90 days after the event. In-person attendance requires advanced registration.
Esperion (NASDAQ: ESPR) has announced significant changes to its Board of Directors. Robert E. Hoffman has been appointed as an independent director, effective immediately, and will serve as Chairperson of the Audit Committee starting May 29, 2025. Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board effective June 1, 2025.
Hoffman brings extensive experience in the biopharmaceutical sector, having served as President, CEO, interim CFO, and Chairperson at Kintara Therapeutics (2021-2024). His previous roles include senior positions at Heron Therapeutics, AnaptysBio, and Arena Pharmaceuticals. He currently serves on the boards of TuHURA Biosciences and Fibrobiologics, and has been a board member for several public and private life sciences companies.
Esperion (NASDAQ: ESPR) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference scheduled for April 7, 2025, at 8:45 a.m. ET. The event will be accessible via webcast through Esperion's website, with replay available for approximately 90 days.
Esperion is a commercial-stage biopharmaceutical company known for developing the only FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk. Their medications are backed by the CLEAR Cardiovascular Outcomes Trial, involving nearly 14,000 patients.
The company is advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi), leveraging new insights into structure and function for rational drug design. Esperion continues to expand globally through commercial execution, international partnerships, and pre-clinical pipeline development.
Esperion (NASDAQ: ESPR) has received FDA alignment to proceed with Phase 3 clinical trials of bempedoic acid, both alone and combined with ezetimibe, for pediatric patients with heterozygous and homozygous familial hypercholesterolemia (HeFH and HoFH).
The company plans to initiate these Phase 3 studies in 2025, following successful completion of Phase 2 clinical study enrollment. The FDA has previously granted orphan drug designation for bempedoic acid in HoFH indication.
This development will allow Esperion to extend its patent protection for an additional six months through June 2031, as part of their lifecycle management plan for bempedoic acid products.
Esperion (NASDAQ: ESPR) reported strong financial results for Q4 and FY 2024, with total revenue growing 186% year-over-year to $332.3 million. U.S. net product revenue increased 48% to $115.7 million for FY24, while Q4 total revenue rose 114% to $69.1 million.
The company's Q4 retail prescription equivalents grew 45% Y/Y and 12% Q/Q, with expanded prescriber base now totaling over 25,000 healthcare practitioners. Esperion announced development of triple combination products with bempedoic acid in the U.S., potentially offering LDL-C lowering exceeding 60%.
Key highlights include:
- Products now approved in 39 countries globally
- Expanded payer access covering 173 million lives
- Otsuka submitted New Drug Application in Japan
- Net loss improved to $51.7 million in FY24 from $209.2 million in FY23
- Cash position strengthened to $144.8 million as of December 31, 2024
Esperion Therapeutics (NASDAQ: ESPR) has entered into a license and distribution agreement with CSL Seqirus for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Australia and New Zealand. The deal includes:
- An upfront payment and milestone payments up to $5 million
- A profitable transfer price for Esperion on product supply
- CSL Seqirus handling commercialization, regulatory approval, and marketing
The partnership targets significant markets where cardiovascular disease affects 1.2 million people in Australia and 175,000 adults in New Zealand. Both medications are indicated to reduce myocardial infarction risk and lower LDL-C in adults with primary hyperlipidemia who cannot take recommended statin therapy.
Esperion (NASDAQ: ESPR) has announced it will report fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opens. Management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
The company is a commercial stage biopharmaceutical firm that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) with allosteric mechanisms.
Esperion (NASDAQ: ESPR) has granted 58,300 restricted stock units (RSUs) to ten new employees under its 2017 Inducement Equity Incentive Plan on February 11, 2025. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments, subject to continued employment.
The grants are specifically designed as employment inducements for new hires who were not previously associated with Esperion, in compliance with NASDAQ Listing Rule 5635(c)(4). Esperion is a commercial-stage biopharmaceutical company that develops and commercializes FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
